Should I buy GSK shares at £14 after the Q3 trading update?

This writer thinks GSK shares appear very cheap after the Q3 results, making him wonder if now’s the time for him to invest in some.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Image source: GSK plc

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

GSK (LSE: GSK) shares fell 3.4% to 1,401p today (30 October) after the drugmaker released a trading update covering the third quarter (Q3).

This means the FTSE 100 stock is down 16% in the past six months and 21% over five years.

Should I invest in GSK shares at £14? Or is this an investment to avoid? Let’s dig in.

Created with Highcharts 11.4.3GSK PriceZoom1M3M6MYTD1Y5Y10YALL30 Oct 201930 Oct 2024Zoom ▾Jan '20Jul '20Jan '21Jul '21Jan '22Jul '22Jan '23Jul '23Jan '24Jul '242020202020212021202220222023202320242024www.fool.co.uk

A mixed Q3

Despite its disappointing share price performance, GSK is still the UK’s eighth-largest listed company. It has a market cap of £58bn and brought in over £30bn in revenue last year.

The company reported a mixed quarter today. Sales of £8.01bn were a little below what analysts were expecting (£8.05bn), but core earnings per share (EPS) of 49.7p grew 5% and beat the forecast EPS of 43.6p.

Specialty Medicines sales grew by 19%, driven by strong performances in oncology (+94%), HIV (+12%), and respiratory/immunology (+14%). Sales in General Medicines rose by 7%, with respiratory treatment Trelegy showing strong growth of 16%.

This year so far, GSK has reported 11 positive phase 3 trials. So the pipeline is strengthening.

Offsetting this, vaccine sales slumped 15%, with shingles jab Shingrix down 7% and Arexvy (for respiratory syncytial virus (RSV) down 72%. Management now expects 2024 vaccine sales to decline by low single-digits, revising its previous forecast of low-to-mid single-digit growth.

The Arexvy development is disappointing for GSK shareholders, as it seemed like a new high-growth market. RSV is a common winter illness and revenue from this new vaccine surpassed £1bn last year.

However, a US advisory committee revised its guidelines for RSV vaccinations earlier this year, essentially capping the market. Meanwhile, Moderna has had its own RSV vaccine approved, along with Pfizer. So there’s a fair bit of competition in that market now.

Zantac settlement

Arguably the biggest development this year is the $2.2bn settlement in the US to end most of its lawsuits in relation to Zantac, the heartburn drug that allegedly caused cancer. This issue has long been a massive black cloud hanging over the stock.

In the quarter, the company booked a £1.8bn charge for the Zantac settlement, which led to a sharp drop in total operating profit. Hence the core bit in the EPS figures.

CEO Emma Walmsley said: “[We] resolved the vast majority of Zantac litigation in the quarter, to remove uncertainty and so we can focus forward. All this means we are on track to deliver our 2024 guidance.”

2024 guidance (constant exchange rates)
Sales+7%-9%
Core operating profit+11%-13%
Core EPS +10%-12%

Would I invest?

There’s always the possibility of further litigation appearing in this industry. It’s a key risk, along with clinical trial setbacks and regulatory changes.

However, the Zantac settlement figure was well below what many first feared. For me, it removes a lot of doubt and distraction.

Despite this, the shares are still trading at a steep discount to peers. In fact, the forward price-to-earnings multiple for 2025 is just 8.4. AstraZeneca‘s is double that.

Meanwhile, GSK expects to declare a full-year dividend of 60p per share. This gives the stock a decent 4.3% dividend yield, which adds further weight to the investment case, in my opinion.

I’ve already got enough sector exposure in my portfolio through Moderna and AstraZeneca. But if I hadn’t, I’d consider buying GSK shares at £14.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Ben McPoland has positions in AstraZeneca Plc and Moderna. The Motley Fool UK has recommended AstraZeneca Plc and GSK. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

2 FTSE 100 and FTSE 250 stocks to consider as stock markets plummet!

Looking for lifeboats as growth-crushing trade tariffs loom? Here are two (including a FTSE 100 gold stock) I think merit…

Read more »

Number three written on white chat bubble on blue background
Investing Articles

Just released: the 3 best growth-focused stocks to consider buying in April [PREMIUM PICKS]

Our goal here is to highlight some of our past recommendations that we think are of particular interest today, due…

Read more »

Happy young plus size woman sitting at kitchen table and watching tv series on tablet computer
Investing Articles

£10,000 invested in Watches of Switzerland shares 1 year ago is now worth…

Watches of Switzerland shares have been decimated by Trump’s tariffs on Switzerland. Dr James Fox explores whether this is an…

Read more »

Hand flipping wooden cubes for change wording" Panic " to " Calm".
Investing Articles

Growth stocks are crashing! Here’s what I’m doing now

Our writer shares his thoughts as growth stocks get crushed, as well as a favourite from the Nasdaq that he…

Read more »

Investing Articles

What’s going on with the Nvidia share price now?

The Nvidia share price is tanking. Once the most valuable listed company, Nvidia has seen more than $1trn wiped off…

Read more »

Investing Articles

This FTSE AIM stock has £2.3bn in net cash, and a market cap of £2.4bn!

I love this FTSE AIM stock, but it really hasn’t delivered for me yet. The stock trades with crazily low…

Read more »

Smart young brown businesswoman working from home on a laptop
Investing Articles

Down 15% in a week! Are these 5 FTSE 100 fallers screaming buys as markets plunge?

Five of Harvey Jones's favourite FTSE 100 stocks all have the same thing in common – they've fallen around 15%…

Read more »

Hand of person putting wood cube block with word VALUE on wooden table
Investing Articles

2 stocks that have been crushed and now offer a ton of value

Edward Sheldon has been scanning the market for stocks that offer value after the sell-off. Here are two shares he…

Read more »